Ranbaxy working on Plan B to get Diovan generic on track?
This article was originally published in Scrip
Executive Summary
Ranbaxy has come up with what's being viewed by some investors as a "cryptic" confirmation of a Plan B underway to surmount the challenges blocking a potential launch of its generic version of Novartis' Diovan (valsartan) in the US after the FDA recently identified certain good manufacturing practice (GMP) deficiencies at it active pharmaceutical ingredients (API) site in Toansa in India.